By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Investment firm Mizuho Securities has initiated coverage of Complete Genomics with an Outperform rating and a 12-month price target of $10.

In a research report issued Wednesday after the close of the market analyst Peter Lawson estimated 2011 revenue at $25.3 million resulting in adjusted loss per share of $2.08, and 2012 revenue at $38.5 million with an adjusted loss per share of $1.78.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.